ClinicalTrials.gg
Not yet recruitingNCT07865221Updated Oct 14, 2026

Pulsed Field Ablation for Paroxysmal Atrial Fibrillation: Clinical Efficacy and Left Atrial Function Protection

An interventional study of Novel Pulsed Field Ablation System and Radiofrequency Ablation Catheter in Paroxysmal Atrial Fibrillation, Pulsed Field Ablation and Catheter Ablation, sponsored by Tianjin Medical University General Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Tianjin Medical University General Hospital · Not applicable, Interventional, and Treatment

How we know

Updated Oct 14, 2026Study documents postedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.

Planned enrollment
131st of 256
220 · median 235
Started
2026
with 47 others
No phase
200 of 377
100 open now
Primary completion
2028-09
later than 148 of 182 live
Registered
373rd of 377
by date

Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 131st largest by planned enrollment of the 256 interventional ones that give a count, is one of 48 that started in 2026, is one of 200 with no phase, reaches primary completion later than 148 of the 182 other live ones, and was the 373rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Atrial Fibrillation with a site in China, or all of them as a file.
02

Study summary

This is a prospective clinical study aiming to evaluate the clinical efficacy and safety of a novel domestic pulsed field ablation (PFA) system in the treatment of paroxysmal atrial fibrillation (PAF), and to specifically assess its protective effect on left atrial function.

Approximately 200-220 patients with paroxysmal atrial fibrillation are planned to be enrolled. Participants will be treated with the novel PFA system (YTL-PFA01) and a three-dimensional electroanatomical mapping system.

The primary objectives include:

Efficacy: Immediate pulmonary vein isolation success rate, and freedom from atrial arrhythmias (>30 seconds) at 12 months post-procedure.

Safety: Incidence of major complications (such as cardiac tamponade, stroke, pulmonary vein stenosis, phrenic nerve palsy).

Left Atrial Function: Dynamic changes in echocardiographic parameters (e.g., LAVI, LVEF, E/A, LASr/cd/ct) and serum biomarkers (e.g., troponin, BNP, inflammatory markers) at multiple time points before and after the procedure.

Patients will be followed up for 12 months to evaluate the long-term outcomes and quality of life improvement (EQ-5D-5L). The study duration is expected to be 36 months (October 2025 to September 2028).

03

Conditions studied

  • Paroxysmal Atrial Fibrillation
  • Pulsed Field Ablation
  • Catheter Ablation
  • Left Atrial Function
  • Cardiology

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >= 18 years.
  2. Symptomatic paroxysmal atrial fibrillation (AF duration \< 7 days).
  3. Ineffective treatment with one or more antiarrhythmic drugs (e.g., propafenone, sotalol, amiodarone).
  4. Discontinued antiarrhythmic drugs for at least 5 half-lives before the procedure.
  5. Willing to receive PFA treatment and postoperative follow-up, and able to sign .

Exclusion criteria

Exclusion Criteria:

  1. Previous radiofrequency catheter ablation (RFCA) for atrial fibrillation.
  2. Presence of a cardiac pacemaker or post-left atrial appendage closure.
  3. Thrombocytopenia ( \< 80×10\^9/L) or to anticoagulation (e.g., warfarin, heparin, direct factor Xa inhibitors, direct thrombin inhibitors).
  4. Left atrial anterior-posterior diameter > 55 mm (by transthoracic echocardiography, parasternal long-axis view).
  5. Left atrial (or left atrial appendage) thrombus (confirmed by TEE or MSCT).
  6. Severe structural heart disease (e.g., hypertrophic obstructive cardiomyopathy, severe valvular heart disease) or uncontrolled heart failure ( class III or IV).
  7. Thyroid dysfunction (e.g., uncontrolled hyperthyroidism).
  8. Severe hepatic or renal impairment ( or ALT >= 3 times ; SCr > 3.5 mg/dl or Ccr \< 30 ml/min).
  9. History of stroke within the past 6 months.
  10. History of surgery within the past 3 months.
  11. Pregnant women.
  12. \< 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    PFA Group

    Patients will be treated with the novel Pulsed Field Ablation system

    Device: Novel Pulsed Field Ablation System

  • Active comparator
    RFCA Group

    Patients will be treated with conventional radiofrequency catheter ablation.

    Device: Radiofrequency Ablation Catheter

Interventions

  • DeviceNovel Pulsed Field Ablation System

    Use a novel PFA system (YTL-PFA01) and a three-dimensional electroanatomical mapping system to perform pulmonary vein isolation.

  • DeviceRadiofrequency Ablation Catheter

    Use conventional radiofrequency ablation catheters to perform pulmonary vein isolation.

06

What researchers measure

Primary outcomes

  1. Freedom from atrial arrhythmia recurrence at 12 months

    Percentage of participants free from documented atrial arrhythmias (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting \>30 seconds at 12 months post-ablation.

    Time frame: 12 months post-procedure

  2. Incidence of major procedure-related complications

    Incidence of major adverse events related to the procedure, such as cardiac tamponade, thromboembolic events, vascular complications, pulmonary vein stenosis, and phrenic nerve injury.

    Time frame: Within 12 months post-procedure

Secondary outcomes

  1. Change in left atrial volume index (LAVI)

    Change from baseline in left atrial volume index (LAVI) at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  2. Change in left ventricular ejection fraction (LVEF)

    Change from baseline in left ventricular ejection fraction (LVEF) at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  3. Change in mitral inflow E/A ratio

    Change from baseline in E/A ratio at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  4. Change in left atrial reservoir strain (LASr)

    Change from baseline in LASr at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  5. Change in tissue Doppler a'/e' ratio

    Change from baseline in a'/e' ratio at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  6. Change in left atrial conduit strain (LAScd)

    Change from baseline in LAScd at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  7. Change in left atrial contractile strain (LASct)

    Change from baseline in LASct at each follow-up visit.

    Time frame: Baseline to 12 months post-procedure

  8. Change in quality of life score

    Change from baseline in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) health-related quality of life questionnaire score. The scale consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). The minimum score for each dimension is 1 (no problems) and the maximum score is 5 (unable to/extreme problems), with a total score range of 5 to 25. Higher scores indicate a worse health-related quality of life outcome.

    Time frame: Baseline to 12 months post-procedure

  9. Change in myocardial injury markers (troponin)

    Change from baseline in troponin at different time points.

    Time frame: Baseline to 12 months post-procedure

  10. Change in inflammatory markers (CRP)

    Change from baseline in C-reactive protein (CRP) at different time points.

    Time frame: From the initial assessment to 12 months after the procedure

  11. Change in inflammatory markers (IL-6)

    Change from baseline in interleukin-6 (IL-6) at different time points.

    Time frame: Baseline to 12 months post-procedure

  12. Change in fibrosis markers (Galectin-3)

    Change from baseline in Galectin-3 at different time points.

    Time frame: Baseline to 12 months post-procedure

  13. Change in fibrosis markers (sST2)

    Change from baseline in soluble ST2 (sST2) at different time points.

    Time frame: Baseline to 12 months post-procedure

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 23 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 8, 2026
StartEst.
Oct 2026
Primary completionEst.
Sep 2028
CompletionEst.
Oct 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Oct 14, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionChange in quality of life score: how it is measured was reworded
Oct 14, 2026
Registered
First appeared on the registry
Oct 8, 2026
Show all 2 updates
  1. Oct 14, 2026
    Documents Study protocol ↗ updated
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionChange in quality of life score: how it is measured was reworded
  2. Oct 8, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07865221
Lead sponsor
Tianjin Medical University General Hospital
Responsible party
Heng Cai (Chief Physician, Tianjin Medical University General Hospital) — Principal investigator
First posted
Oct 8, 2026
Start date
Oct 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Heng Cai, Master
Contact
yuong1101@163.com
+86 13821378394
Xue Li
Contact
xuelizyy@tmu.edu.cn
+86 13752697996

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion